-
Primary Prevention Trial Designs Using Coronary Imaging: A National Heart, Lung, and Blood Institute WorkshopP Greenland, ED Michos, N Redmond et al. -
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular DiseaseA Prespecified Analysis From the FOURIER TrialMurphy SA, Pedersen TR, Gaciong ZA et al.
-
Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesWanner C, Inzucchi SE, EMPA-REG OUTCOME Investigators.
-
Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyPerkovic V, Jardine MJ, CREDENCE Trial Investigators.
-
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysisSuchard MA, Schuemie MJ, Krumholz HM et al.
-
Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular DiseaseE Ajufo, CR Ayers, R Vigen et al.
-
The sinus venosus contributes to coronary vasculature through VEGFC-stimulated angiogenesisHI Chen , B Sharma, K Red-Horse et al.
-
Association Between Depressive Symptoms and Incident Cardiovascular DiseasesEL Harshfield, L Pennells, Emerging Risk Factors Collaboration.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
